Co-enzyme Q10 and idebenone use in Friedreich's ataxia.

Michael H Parkinson, Jörg B Schulz, Paola Giunti

Journal: Journal of neurochemistry 2013;126 Suppl 1():125-41

PMID: 23859348

Abstract

Friedreich's ataxia is a debilitating progressive neurodegenerative disease associated with cardiomyopathy and other features. The underlying cause is a deficiency of the mitochondrial protein frataxin which causes mitochondrial iron deposition, increased oxidative stress and impaired adenosine triphosphate production. Over the last 15 years, multiple clinical trials have assessed the efficacy of antioxidant agents in this disease. This article reviews trials of the two most important agents, namely co-enzyme Q10 and idebenone.

© 2013 International Society for Neurochemistry.

Address: Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.